Marker Therapeutics

Marker Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of next-generation T cell-based immunotherapies for blood cancers and solid tumors. The company's core Multi-Antigen Recognizing T cell (MAR-T cell) platform was developed at Baylor College of Medicine and uses non-genetically engineered T cells to simultaneously recognize multiple tumor-specific antigens. Marker's lead product candidate, MT-601, targets six antigens (Survivin, PRAME, NY-ESO-1, MAGE-A4, SSX2, WT-1) and is in a Phase 1 clinical study in lymphoma patients who have relapsed or are ineligible for anti-CD19 CAR-T therapy. The MAR-T approach has been studied in hundreds of patients across seven indications, demonstrating a strong safety profile and durable anti-tumor responses.